Inpharma 1660 - 18 Oct 2008 Hyaluronic acid relieves OA knee pain Results of the FLEXX trial, presented at the Osteoarthritis Research Society International’s 2008 World Congress, show that the use of 1% hyaluronic acid [Euflexxa] is superior to intra-articular saline for the relief of pain in knee osteoarthritis. Euflexxa is the first non-avian derived hyaluronic acid approved in the US for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative, non-pharmacologic treatment and simple analgesics. The 26-week, randomised, saline-controlled study included 586 patients who were evaluated prior to and after three-weekly intra-articular injections of hyaluronic acid (n = 291) or buffered saline. After 26 weeks, patients receiving hyaluronic acid showed a significant improvement in pain after the 50-foot walk compared to patients receiving saline (p = 0.004). There were 10 serious adverse events in the hyaluronic acid group compared with 9 in the saline group. Ferring Pharmaceuticals Inc. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period. Media Release : 7 Oct 2008. Available from: URL: http:// www.ferringusa.com 809093849 1 Inpharma 18 Oct 2008 No. 1660 1173-8324/10/1660-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Hyaluronic acid relieves OA knee pain

Download PDF Report

View
214
Download
1

Embed Size (px)

Citation preview

Inpharma 1660 - 18 Oct 2008

Hyaluronic acid relieves OA kneepain

Results of the FLEXX trial, presented at theOsteoarthritis Research Society International’s 2008World Congress, show that the use of 1% hyaluronicacid [Euflexxa] is superior to intra-articular saline for therelief of pain in knee osteoarthritis. Euflexxa is the firstnon-avian derived hyaluronic acid approved in the USfor the treatment of pain caused by knee osteoarthritisand is indicated for a three-injection treatment regimenfor patients who have failed to respond adequately toconservative, non-pharmacologic treatment and simpleanalgesics.

The 26-week, randomised, saline-controlled studyincluded 586 patients who were evaluated prior to andafter three-weekly intra-articular injections of hyaluronicacid (n = 291) or buffered saline.

After 26 weeks, patients receiving hyaluronic acidshowed a significant improvement in pain after the50-foot walk compared to patients receiving saline(p = 0.004). There were 10 serious adverse events in thehyaluronic acid group compared with 9 in the salinegroup.Ferring Pharmaceuticals Inc. Study Shows EUFLEXXA(R) Patients ReportSignificant Improvements in Osteoarthritis of the Knee Pain over a Six MonthPeriod. Media Release : 7 Oct 2008. Available from: URL: http://www.ferringusa.com 809093849